Aurinia Pharmaceuticals Stock Today
| AUPH Stock | USD 8.85 0.14 1.61% |
Performance12 of 100
| Odds Of DistressLess than 12
|
Aurinia Pharmaceuticals is trading at 8.85 as of the 27th of November 2024. This is a 1.61 percent increase since the beginning of the trading day. The stock's open price was 8.71. Aurinia Pharmaceuticals has less than a 12 % chance of experiencing some financial distress in the next two years of operation and had a good performance during the last 90 days. Equity ratings for Aurinia Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 28th of October 2024 and ending today, the 27th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 26th of January 1999 | Category Healthcare | Classification Health Care |
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company has 143.18 M outstanding shares of which 7.34 M shares are presently shorted by private and institutional investors with about 5.52 trading days to cover. More on Aurinia Pharmaceuticals
Moving together with Aurinia Stock
| 0.84 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
Moving against Aurinia Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Aurinia Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Peter MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAurinia Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Aurinia Pharmaceuticals' financial leverage. It provides some insight into what part of Aurinia Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Aurinia Pharmaceuticals (AUPH) is traded on NASDAQ Exchange in USA. It is located in 118 Avenue , 14315, Edmonton, AB, Canada, T5L 4S6 and employs 300 people. Aurinia Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.25 B. Aurinia Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 143.18 M outstanding shares of which 7.34 M shares are presently shorted by private and institutional investors with about 5.52 trading days to cover.
Aurinia Pharmaceuticals currently holds about 391.51 M in cash with (33.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.76.
Check Aurinia Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationAurinia Pharmaceuticals holds a total of 143.18 Million outstanding shares. 30% of Aurinia Pharmaceuticals outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Aurinia Ownership Details
Aurinia Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Schroder Investment Management Group | 2024-06-30 | 997.2 K | |
| Northern Trust Corp | 2024-09-30 | 995.7 K | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 744 K | |
| Citigroup Inc | 2024-09-30 | 654.2 K | |
| Woodline Partners Lp | 2024-06-30 | 614.1 K | |
| Segall Bryant & Hamill | 2024-09-30 | 562.8 K | |
| Sg Americas Securities, Llc | 2024-09-30 | 547.7 K | |
| Citadel Advisors Llc | 2024-09-30 | 546.9 K | |
| Jpmorgan Chase & Co | 2024-06-30 | 507 K | |
| Blackrock Inc | 2024-06-30 | 9.3 M | |
| Armistice Capital, Llc | 2024-09-30 | 8.2 M |
Aurinia Pharmaceuticals Historical Income Statement
Aurinia Stock Against Markets
Aurinia Pharmaceuticals Corporate Management
| Chris Hays | VP Marketing | Profile | |
| Premchandran Ramiya | Senior Chain | Profile | |
| Joseph CPA | Chief Officer | Profile | |
| Ann Daus | Senior Quality | Profile | |
| Andrea Christopher | Head Relations | Profile | |
| Michael Martin | Chief Officer | Profile |
Already Invested in Aurinia Pharmaceuticals?
The danger of trading Aurinia Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Aurinia Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Aurinia Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Aurinia Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Aurinia Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aurinia Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aurinia Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aurinia Pharmaceuticals Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aurinia Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aurinia Pharmaceuticals. If investors know Aurinia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aurinia Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 1.536 | Quarterly Revenue Growth 0.243 | Return On Assets (0.02) | Return On Equity (0.06) |
The market value of Aurinia Pharmaceuticals is measured differently than its book value, which is the value of Aurinia that is recorded on the company's balance sheet. Investors also form their own opinion of Aurinia Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aurinia Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aurinia Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aurinia Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aurinia Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aurinia Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aurinia Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.